Company Profile

Industry Sector: Biotechnology

Company Overview: WinSanTor is a clinical stage biotechnology company based out of San Diego developing treatments of first in-class therapies to prevent and reverse Peripheral Neuropathy.

Target Market: Peripheral Neuropathy patients.

Key Value Drivers

Technology: WinSanTor has identified a novel pathway eliciting neuropathy, and more importantly, a class of neuroprotective and neuroregenerative compounds that modulate this pathway to PREVENT AND REVERSE peripheral neuropathy. These are the basis for WinSanTor’s proprietary and extensive portfolio of potential therapeutic drugs; with our lead (WST1 - topical treatment for diabetic neuropathy) slated to begin Phase 1 trials in mid-2016.

Competitive Advantage: WinSanTor is the assembly of the leading researchers and clinicians in diabetic neuropathy, a disease with no known cure, having amassed the know-how of the last two decades in the space and redirected this energy to developing a potential cure. Our IP is not only around the first-in-class, but the entire class of modulators in the space.

Plan & Strategy: Peripheral neuropathy is a global dilemma affecting hundreds of millions of people. The largest subset, diabetic peripheral neuropathy affects nearly 2/3rds of diabetics, with the largest concentration in Asia. WST is actively pursuing Asian partnership opportunities, with the goal to upload the program to a major international partner by 2017 for Ph-3 studies. WST has begun discussions with NGO & government stakeholders to support certain Ph-3 studies.

Management

Leadership:
Stanley Kim, Founder/CEO, seasoned entrepreneur
Angela Hansen, Dir Reg, 20+ years regulatory
Nigel Calcutt, PhD, Founder, Prof Pathology UCSD (DPN)
Paul Fernyhough, PhD, Founder, Dir/Prof UoM
Lakshmi Kotra, PhD, Founder, Dir. Univ. Toronto

Scientific Advisory Board
Dr. Rayaz Malik – Weill Cornell Medical
Dr. Aaron Vinik – Eastern Virginia Medical

Business Advisory Board
Peter Farrell – Founder/Chairman ResMed Inc
Marc Hodosh – Founder TEDMED
Dan Ross – President IMS Health Capital
Jonathan Scheff – Former CMO HealthNet